Nurix Therapeutics
NRIX
173 hedge funds and large institutions have $1.36B invested in Nurix Therapeutics in 2024 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 61 increasing their positions, 45 reducing their positions, and 18 closing their positions.
194% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 18
88% more capital invested
Capital invested by funds: $721M → $1.36B (+$635M)
36% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 45
24% more funds holding
Funds holding: 139 → 173 (+34)
9.17% more ownership
Funds ownership: 100.4% → 109.57% (+9.2%)
54% less call options, than puts
Call options by funds: $1.05M | Put options by funds: $2.28M
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$46.2M |
| 2 |
BlackRock
New York
|
+$34.9M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$34.1M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$20M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.2M |
Top Sellers
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$16.6M |
| 2 |
Morgan Stanley
New York
|
-$8.43M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.02M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$5.9M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$5.66M |
NRIX Hedge Fund Activity: Q2 2024 in Review
173 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2024, worth a combined $1.36B — up 88% from $721M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new NRIX positions and 18 closed out — a net gain of 35 holders — while 61 added to existing stakes and 45 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $46.2M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $16.6M sold.
- 173 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2024, up from 139 in Q1 2024.
- Funds reported $1.36B of Nurix Therapeutics stock for Q2 2024, up 88% quarter-over-quarter.
- 53 funds opened new Nurix Therapeutics positions in Q2 2024 and 18 closed out, a net change of +35 holders.
- The largest Nurix Therapeutics buyer in Q2 2024 was Wellington Management Group, an estimated $46.2M added.
- The largest Nurix Therapeutics seller in Q2 2024 was Bain Capital Life Sciences Investors, an estimated $16.6M sold.
Based on aggregated 13F filings for Q2 2024.